// App-Quantinova.ai

1087 : Etirinotecan pegol (EP) target-specific pharmacodynamic (PD) biomarkers measured in circulating tumor cells (CTCs) from patients in the phase III BEACON study in patients with metastatic breast cancer (mBC).

Researchers

Presenter

  • Ute Hoch

Principal Investigators

  • Dennis G. Fry

  • Yen Lin Chia

  • Seock-Ah Im

  • Binghe Xu

  • Kenna Lynn Anderes

  • Edith A. Perez

  • Javier Cortez

  • Ahmad Awada

  • Joyce O'Shaughnessy

  • Christopher Twelves

  • Hope S. Rugo

  • Darren W. Davis

  • Katie Caygill

  • Alison L. Hannah

Medical Centers

  • Consultant, Sebastopol, CA

  • Mayo Clinic, Jacksonville, FL

  • Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, ChinaDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, South KoreaUniversity of Leeds and St. Jamess University Hospital, Leeds, United Kingdom

  • Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX

  • University of California, San Francisco, San Francisco, CA

  • Nektar Therapeutics, San Francisco, CA

  • Vall d'Hebron Institute of Oncology, Barcelona, Spain

  • ApoCell, Inc., Houston, TX

  • Medical Oncology Clinic, Jules Bordet Institute, Brussels, Belgium

Locations

  • United States

  • Spain

  • United Kingdom

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • ATP-binding cassette super-family G member 2

  • Peripheral blood mononuclear cell

  • Circulating tumor cells

  • Cluster of differentiation 45

Drug/Treatment

  • etirinotecan pegol

  • SN38

  • DMSO

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT01492101

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved